Regeneron Shares Dip Amid Market Shift, but Pipeline & Collaborations Keep Long‑Term Appeal
Regeneron shares dip as markets shift to defensive stocks, but the firm’s robust gene‑therapy pipeline and strategic biotech collaborations keep it a long‑term growth play.
- REGENERON PHARMACEUTICALS
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read